Humacyte Reports Third Quarter Earnings Beat on Revenue and EPS
Humacyte (NASDAQ: HUMA) reported third-quarter financial results that exceeded analyst expectations. The company posted a GAAP earnings per share (EPS) of -$0.06, beating estimates by $0.03, while revenue reached $1.03 million, representing a 37.3% increase year-over-year and surpassing projections by $0.26 million. Looking ahead, the company provided optimistic guidance regarding its Symvess product line. Humacyte expects Q4 sales for Symvess to at least double its Q3 sales of $1 million. The firm also anticipates further expansion in its commercial footprint during the upcoming period.
Tickers: $HUMA